Eli Lilly (NYSE:LLY) recently announced leadership transitions, including new roles for Ilya Yuffa, Patrik Jonsson, and ...

Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Behind Lilly's decline ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra. In this article, we will summarize the ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to expect from LLY's Q1 results.

Over the last couple of years, one of the best pharma stocks to own has been Eli Lilly ( LLY -3.19%). But now, an investment in Lilly may not look so enticing as the possibility of more tariffs loom.

Lilly announced several changes to its executive leadership team. 1 These changes are mostly related to the company’s ...

Beyond GLP-1, Lilly’s $11 billion research and development investments power a diverse pipeline. Its Alzheimer’s drug Kisunla that received FDA approval in 2024, targets a $20 billion market, while ...

head of Lilly Oncology. The agreement isn't Lilly's first attempt to make a mark in the PI3K inhibitor class, having previously been working on LOXO-783, a drug it acquired as part of its $8 ...

David Ricks; Chairman of the Board, President, Chief Executive Officer; Eli Lilly and Co Lucas Montarce; Executive Vice President and Chief Financial Officer; Eli Lilly and Co Daniel Skovronsky; ...

Under terms of the deal, Alchemab will lead early Phase I trials for ATLX-1282 in amyotrophic lateral sclerosis, while Lilly ...

Alchemab Therapeutics, whose labs are in Cambridge UK, stands to scoop $415 million from Eli Lilly and Company following a ...

Mounjaro, Zepbound, and Jardiance in the cardiometabolic category, Taltz in immunology, and Verzenio in oncology are the future of Lilly’s growth. While the aforementioned are the safer bets ...